Skip to main content
Premium Trial:

Request an Annual Quote

GenomeWeb Index Bounces Back in October, Led by Rebound in Berkeley Lights Stock

NEW YORK – After taking a 7 percent downswing in September, the GenomeWeb Index swung back up in October, reflecting growth in the broader markets as it gained more than 3 percent.

The index underperformed the Dow Jones Industrial Average and the Nasdaq, which rose 6 percent and 7 percent last month, respectively. But it outperformed the Nasdaq Biotechnology Index, which fell nearly 2 percent. The performance of individual stocks in the GenomeWeb Index was mixed in October, as 17 of the 35 stocks saw losses and 18 saw gains.

Berkeley Lights led the gainers in October with a 19 percent increase in share price, followed by Twist Bioscience and Thermo Fisher Scientific, which both rose 11 percent. Berkeley Lights had led the decliners in September with a 45 percent drop in stock price. This is Thermo Fisher's second month in a row on the list of top three gainers — the company's stock rose 3 percent last month.

Fluidigm led the decliners in October with a 22 percent drop in stock price, followed by Burning Rock Biotech (-21 percent) and CareDx (-20 percent).

Berkeley Lights' shares bounced back after the company reported mid-month that it expects preliminary third quarter revenue growth of approximately 33 percent. For the three months ended Sept. 30, the company expects record total revenues in the range of $24 million to $24.3 million and said it placed 13 platforms, including three subscriptions, also a record.

In September, the stock had taken a 30 percent tumble in two days after Scorpion Capital published a short-selling report accusing the company of "fleecing customers and IPO bagholders with a $2 million black box that's a clunker, while insiders and Silicon Valley bigwigs race[d] to dump stock."

Though this report caused the stock to take a very sharp downturn, investment analysts who cover the firm said the company's business proposition remains intact, and they expressed optimism about its long-term prospects.

Twist Bio's most significant news last month was that it had agreed to collaborate with Centogene to develop and commercialize sequencing assay kits for rare disease genetic testing. The assays will combine Centogene's experience in rare disease diagnostics with Twist's target enrichment capabilities for next-generation sequencing library preparation, and the partners will design multiple tests and will attempt to make genetic testing more accessible to patients.

Thermo Fisher's shares rose after the company reported that its third quarter revenues rose 9 percent year over year, due to increases in its life sciences solutions, analytical instruments, and laboratory products and services segments. Total revenues for the quarter were $9.33 billion, beating the average Wall Street estimate of $8.39 billion.

In an analyst note, SVB Leerink's Puneet Souda wrote that the firm is "leveraging unmatched scale and reach into the labs, combined with a number of growth products serving key end markets and a growing consolidator position."

On the side of the decliners, there was no clear reason for the decline in either Fluidigm's or Burning Rock's shares. Neither company reported any news of significance in October.

CareDx's decline came after the release of its Q3 earnings. Despite showing growth of 42 percent in its revenues, the company also disclosed in a filing with the US Securities and Exchange Commission that it is under investigation about its business practices by the US Department of Justice and the SEC.

The DOJ is conducting a False Claims Act investigation into the company's kidney testing and phlebotomy services, it said in the filing. The firm also received a subpoena from the SEC for a related investigation and a request for information from a state regulatory agency.

Company Ticker 29-Oct-21 30-Sep-21 % change
Adaptive Biotechnologies ADPT 33.41 33.99 -1.71
Agilent Technologies A 157.49 157.53 -0.03
Becton Dickinson BDX 239.59 245.82 -2.53
Berkeley Lights BLI 23.25 19.56 18.87
Bio-Rad Laboratories BIO 794.68 745.95 6.53
Bio-Techne TECH 523.65 484.57 8.06
Bruker BRKR 80.30 78.10 2.82
Burning Rock Biotech BNR 14.09 17.88 -21.20
CareDx CDNA 51.00 63.37 -19.52
Castle Biosciences CSTL 62.35 66.50 -6.24
Danaher DHR 311.77 304.44 2.41
Exact Sciences EXAS 95.22 95.45 -0.24
Fluidigm FLDM 5.15 6.59 -21.85
Fulgent Genetics FLGT 82.92 89.95 -7.82
Genetron GTH 13.77 13.85 -0.58
Guardant Health GH 116.79 125.01 -6.58
Hologic HOLX 73.31 73.81 -0.68
Illumina ILMN 415.06 405.61 2.33
Invitae NVTA 26.50 28.43 -6.79
Meridian Bioscience VIVO 18.81 19.24 -2.23
Myriad Genetics MYGN 30.77 32.29 -4.71
NanoString Technologies NSTG 48.30 48.01 0.60
Natera NTRA 114.57 111.44 2.81
NeoGenomics Laboratories NEO 46.00 48.24 -4.64
Pacific Biosciences PACB 26.48 25.55 3.64
Personalis PSNL 19.62 19.24 1.98
PerkinElmer* PKI 176.89 173.29 2.08
Qiagen QGEN 55.76 51.68 7.89
Quanterix QTRX 50.61 49.79 1.65
Quidel QDEL 132.77 141.15 -5.94
Thermo Fisher Scientific TMO 633.07 571.33 10.81
Twist Bioscience TWST 118.80 106.97 11.06
Veracyte VCYT 47.88 46.45 3.08
Waters WAT 367.55 357.30 2.87
10x Genomics TXG 161.27 145.58 10.78
GenomeWeb Index Average   147.70 142.97 3.31
         
*PerkinElmer paid a dividend of $.07 per share on Oct. 21    

 

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.